PPT-62-year-old man with metastatic castration sensitive prostate cancer

Using PSMAPET for accurate staging in biochemical recurrent metastatic prostate cancer Case courtesy of Associate Professor Yao ZHU Fudan University Shanghai Cancer Center Photo by  Hobi. Alexandre . Iscaife. ; Denis Reis Morais; Sabrina Thalita Reis; Nayara Izabel Viana, . Andre. . Bordini. ; Daniele . Janolli. ; Nelson . Dip. ; Miguel . Srougi. ; Katia Ramos Moreira Leite . Laboratory of Medical Research – LIM 55, Urology, University of Sao Paulo, Sao Paulo, Brazil. This program will include a discussion of . off-label treatments and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. . ADVANCED PROSTATE CANCER: BONE ISSUES AND METASTASES Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine Castrate-sensitive Non-Metastatic VeruInc The Prostate Cancer Company Novel MedicinesVeru Corporate PresentationJune 2020Thiscommunicationcontainsforward-lookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995 VeruInc The Prostate Cancer Company Novel MedicinesMarch 2019Oppenheimer Healthcare Conference2Forward looking statementsThis communication contains forward-looking statements within the meaning of th Investigations for Prostate cancer Presentation: Diagnosis: Risk stratification (Ref) : Low risk PSA 0, Gleason score 6 (ISUP 1), DRE showing cT1 - T2a Intermediate risk: PSA 10 - 20, –. To treat . or not to treat. Dr Oliver Klein – Medical Oncologist. Prostate Cancer. |. . Epidemiology- Australia. Most common cancers 2012 . Cancer related deaths 2010 . Australian Institute of Health and Welfare. Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced . CSPC. Supported by an educational grant from Astellas and Pfizer, Inc.. EPISODE 3. Cora N. Sternberg MD, FACP. Clinical Director, . m. CSPC). 1. Neal Shore, MD, FACS. Carolina Urologic Research Center. Myrtle Beach, SC. Alicia Morgans, MD, MPH. Northwestern University. Chicago, IL. PROSTATE CANCER IS HORMONE DEPENDENT. 2. Huggins CB. Nobel lecture. Available from . Francesco GIAMMARILE. « . Aut tace aut loquere meliora silentio.  ». Bone scan and F-Choline . Radionuclide treatment . Presentation Outline. Introduction. NO CONFLICT OF INTEREST. General aspects. Clinical implementation of testing and PARP. i. monotherapy, and the patient journey for prostate cancer patients. Dr Neal Shore. , . MD, FACS. Carolina Urologic Research Center and Chief Medical Officer for Genesis Care, USA. Foundation Medicine. ctDNA. is good information for somatic mutations in . mCRPC. when biopsy is not possible. lots of other data on the importance of CTCs as predictive. 93% concordance for BRCA1/2 for tissue and liquid biopsy – . Jeanny B. Aragon-Ching, M.D., F.A.C.P.. Clinical Program Director of Genitourinary Cancers, Inova . Schar. Cancer Institute. Associate Professor of Medicine, Virginia Commonwealth University. October 13, 2018. nm. CRPC patients and the healthcare team. GUIDE COMMUNICATION FRAMEWORK - . Part 3. Dr.. Jason Alcorn, D. . Nurs. , FHEA, MSc, BSc. Mid Yorkshire Hospitals NHS Trust, UK. NOVEMBER 2021. nmCRPC, non-metastatic castration-resistant prostate cancer.